Table 1b Association of platelet response rates and transfusion needs with various platelet response criteria

Platelet response criteria	Response rate				Platelet transfuse RR ^a (95% CI)	Bleeding ^b		OS ^c
	Placebo N=83, n (%)	Romiplostim N=167, n (%)	P-value	OR (95% CI) ^b		All RR (95% CI)	CSBE RR (95% CI)	HR (95% CI)
IWG 2006 HI-P	3 (3.6)	61 (36.5)	<0.001	15.6* (4.7–51.8)	9.8* (7.8–12.3)	2.3* (2.1–2.6)	1.4* (1.0–2.0)	2.6* (1.4–4.7)
IWG 2000 Major or Minor	2 (2.4)	56 (33.5)	<0.001	21.2* (5.0–90.3)	13.0* (9.8–17.2)	2.5* (2.2–2.8)	1.2 (0.8–1.6)	2.2* (1.2–4.1)
Italian MDS group
Complete (IWG AML 2003)	4 (4.8)	63 (37.7)	<0.001	15.4* (5.0–47.2)	5.8* (4.7–7.2)	2.6* (2.3–2.9)	1.8* (1.2–2.7)	1.9* (1.0–3.4)
Any	26 (31.3)	115 (68.9)	<0.001	5.1* (2.8–9.1)	2.6* (2.3–2.9)	2.1* (1.9–2.3)	1.2 (0.9–1.7)	1.5 (0.9–2.6)
Durable	4 (4.8)	82 (49.1)	<0.001	19.7* (6.9–56.5)	9.5* (7.8–11.4)	2.5* (2.3–2.7)	1.8* (1.3–2.4)	2.2* (1.2–3.8)
CALGB	6 (7.2)	75 (44.9)	<0.001	12.5* (4.9–31.5)	1.8* (1.6–2.0)	2.8* (2.5–3.1)	0.8 (0.6–1.1)	1.6 (0.9–2.9)
ITP	17 (20.5)	95 (56.9)	<0.001	6.3* (3.2–12.4)	2.8* (2.4–3.2)	2.1* (1.9–2.3)	0.9 (0.7–1.2)	1.6 (0.9–2.9)

Abbreviations: AML, acute myeloid leukemia; CALGB, Cancer and Leukemia Group B; CI, confidence interval; CSBE, clinically significant bleeding event; HI-P, hematologic improvement—platelet; HR, hazard ratio; IPSS, International Prognostic Scoring System; ITP, immune thrombocytopenia; IWG, International Working Group; MDS, myelodysplastic syndrome; OR, odds ratio; OS, overall survival; RR, rate ratio.
^aRomiplostim-treated patients only, responders vs nonresponders; adjusted for baseline platelet count and IPSS status.
^bRomiplostim vs placebo; adjusted for baseline platelet count and IPSS status.
^cRomiplostim-treated patients, nonresponders vs responders; adjusted for baseline age (65 years or older) and IPSS status. Statistically significant OR and RR are bolded with asterisks.

Search